{
  "pmcid": "4913404",
  "sha256": "40cf448f5c446f1c22ddc5d05483344b68afb6f34533f206c72d546744e40292",
  "timestamp_utc": "2025-11-09T22:44:30.253625+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.788775921658988,
    "reading_ease": 20.36030673963134,
    "word_count": 217
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sumatriptan for Postoperative Recovery After Microvascular Decompression"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised controlled trial included 50 patients"
      },
      "Participants": {
        "score": 1,
        "evidence": "patients experiencing postoperative headaches after MVD"
      },
      "Intervention": {
        "score": 2,
        "evidence": "subcutaneous injection of sumatriptan (6 mg) or saline"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effect of sumatriptan on postoperative recovery quality."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the Quality of Recovery-40 (QoR-40) score at 24 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Both patients and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Fifty patients were randomised: 25 to the sumatriptan group and 25 to the placebo group."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Fifty patients were randomised: 25 to the sumatriptan group and 25 to the placebo group."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The sumatriptan group had significantly higher QoR-40 scores (median 184; interquartile range 169–196) compared to the placebo group (133; 119–155; P <0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild and occurred in 3/25 (12%) of the sumatriptan group and 1/25 (4%) of the placebo group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01632657."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}